×

Business / Stock Market

Corvus Posts Data From Discontinued Mupadolimab COVID-19 Program

Published Sep 22 2021 at 11:35 AM GMT

Business Insider

Business Insider @businessinsider.com

Add to Collections
Report Post

Continue reading at businessinsider.com

Key
Points

Corvus Pharmaceuticals Inc (NASDAQ:CRVS) has shared data from the Phase 3 mupadolimab COVID-19 trial.

Credit

Tags

Continue reading at businessinsider.com

Posted in Business, Stock Market

Stats

Published Sep 22, 2021 11:35 AM GMT